Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:35:46.813Z.
Calculation as of: 2026-10-06T20:35:46.813Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9f471510e2ba483dadfaa738129fdacbeb72ec081face8194c47abf0e776528
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$6.60M
EV/FCF Ratio
N/A
TTM Avg
1251.36x
3Y Avg
3596.80x
5Y Avg
3596.80x
Market Cap
$6.58M
EV/FCF Ratio
N/A
TTM Avg
2102.49x
3Y Avg
2468.48x
5Y Avg
5853.17x
Market Cap
$7.07M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.74M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.61M | N/A | 126.41x | 126.41x | 126.41x |
| Exicure, Inc. (XCUR)vs › | $6.88M | N/A | 2752.61x | 2752.61x | 2752.61x |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | N/A | 1251.36x | 3596.80x | 3596.80x |
| Aclarion, Inc. (ACON)vs › | $6.60M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A | 2102.49x | 2468.48x | 5853.17x |
| KALA BIO, Inc. (KALA)vs › | $7.04M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.15M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute